Last Update: Mar 06, 2025
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR)
ClinicalTrials.gov Identifier:
Novartis Reference Number:CAIN457C22301E1
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. The study will consist of an up to 4-week screening period, an up to 2-year Treatment Period which includes two Treatment Periods, and a 16-week treatment-free follow-up period (20 weeks post last dose of secukinumab).

Treatment period:

There will be two Treatment Periods (TPs): TP1 will be from the first dose administration of secukinumab (Baseline) to Week 24, where visits will occur every 4 weeks, and TP2 will be from post Week 24 visit (post-dose) to up to 2 years. Participants will return to the study site every 4 weeks from Baseline until Week 24 (Weeks 16 and 20 visits are optional on-site visits and needed when participants are unwilling/uncomfortable to self-administer study treatment at home/offsite), then every 12 weeks afterwards in TP2 for resupply of study medication but may return earlier if needed (i.e., those participants who are unwilling/uncomfortable to self-administer study treatment can continue to visit site every 4 weeks for drug administration if they wish to do so).

Follow-up period: An EoS visit (20 weeks after last administration of secukinumab) will be done for all participants, regardless of whether they complete the entire study as planned, or they discontinue prematurely.

Polymyalgia Rheumatica
Phase3
Recruiting
300
Jun 28, 2024
Feb 10, 2028
All
50 Years - 100 Years (Adult, Older Adult)

Interventions

Biological

Secukinumab

2 x 150mg/1mL PFS secukinumab

Eligibility Criteria

Inclusion Criteria:

* Participants who have completed 52-week Treatment Period as per protocol in a Novartis study of secukinumab in PMR patients (the "core study" - Study CAIN457C22301), AND

* who have experienced a relapse during the treatment-free follow-up period of the core study, AND
* who have not been on rescue treatment.
* The participant would potentially derive benefit from secukinumab, and the benefit outweighs the risk, based on the investigator's judgement.

Exclusion Criteria:

* Use of prohibited medications, as specified in the protocol
* History of ongoing, chronic or recurrent infectious disease (i.e., human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), active tuberculosis infection (TB))
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
* Live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster vaccines) within 6 weeks prior to Baseline
* Subjects whose participation in the extension study could expose them to an undue safety risk

Novartis Investigative Site

Recruiting

Quilmes,Buenos Aires,B1878geg,Argentina

Novartis Investigative Site

Recruiting

Parramatta,2150,Australia

Novartis Investigative Site

Recruiting

Southport,Queensland,4215,Australia

Novartis Investigative Site

Recruiting

Heidelberg Heights,Victoria,3081,Australia

Novartis Investigative Site

Recruiting

Quebec,G1v 3m7,Canada

Novartis Investigative Site

Recruiting

Santiago,7500571,Chile

Novartis Investigative Site

Recruiting

Barranquilla,080020,Colombia

Novartis Investigative Site

Recruiting

Bogota,110221,Colombia

Novartis Investigative Site

Recruiting

Praha 2,128 50,Czechia

Novartis Investigative Site

Recruiting

Uherske Hradiste,686 01,Czechia

Novartis Investigative Site

Recruiting

Brno,63800,Czechia

Novartis Investigative Site

Recruiting

Gandrup,9362,Denmark

Novartis Investigative Site

Recruiting

Vejle,Dk-7100,Denmark

Novartis Investigative Site

Recruiting

Toulon Cedex 9,Val De Marne,83800,France

Novartis Investigative Site

Recruiting

Reims,51092,France

Novartis Investigative Site

Recruiting

Strasbourg,67000,France

Novartis Investigative Site

Recruiting

Cholet,49325,France

Novartis Investigative Site

Recruiting

Toulouse,31059,France

Novartis Investigative Site

Recruiting

Herne,44649,Germany

Novartis Investigative Site

Recruiting

Berlin,13125,Germany

Novartis Investigative Site

Recruiting

Berlin,13353,Germany

Novartis Investigative Site

Recruiting

Ratingen,40878,Germany

Novartis Investigative Site

Recruiting

Veszprem,8200,Hungary

Novartis Investigative Site

Recruiting

Budapest,1027,Hungary

Novartis Investigative Site

Recruiting

Pavia,PV,27100,Italy

Novartis Investigative Site

Recruiting

Reggio Emilia,RE,42123,Italy

Novartis Investigative Site

Recruiting

Perugia,PG,06129,Italy

Novartis Investigative Site

Recruiting

Asahikawa-city,Hokkaido,070-8644,Japan

Novartis Investigative Site

Recruiting

Bunkyo ku,Tokyo,113-8431,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,814 0180,Japan

Novartis Investigative Site

Recruiting

Fuchu,Tokyo,183-8524,Japan

Novartis Investigative Site

Recruiting

Kawachinagano,Osaka,586-8521,Japan

Novartis Investigative Site

Recruiting

Ome,Tokyo,198-0042,Japan

Novartis Investigative Site

Recruiting

Shimonoseki,Yamaguchi,750-0041,Japan

Novartis Investigative Site

Recruiting

Okayama,700-8607,Japan

Novartis Investigative Site

Recruiting

Chuo,Yamanashi,409-3898,Japan

Novartis Investigative Site

Recruiting

Ashrafieh,166830,Lebanon

Novartis Investigative Site

Recruiting

Valencia,Comunidad Valenciana,46010,Spain

Novartis Investigative Site

Recruiting

Madrid,28009,Spain

Novartis Investigative Site

Recruiting

La Coruna,Galicia,15006,Spain

Novartis Investigative Site

Recruiting

Sabadell,Barcelona,08208,Spain

Novartis Investigative Site

Recruiting

Basel,4031,Switzerland

Novartis Investigative Site

Recruiting

St Gallen,9007,Switzerland

Rheumatology Associates of South Florida

Recruiting

Boca Raton,Florida,33486,United States

Heather Gliatta
Shawn Baca

Sun Valley Arthritis Center Ltd

Recruiting

Peoria,Arizona,85381,United States

Joy Schechtman

Klein and Associates

Recruiting

Hagerstown,Maryland,21740,United States

Katie M Alvord
Mary Howell

Arthritis Center of North Georgia

Recruiting

Gainesville,Georgia,30501,United States

Angelica Garza
Brent Flickinger

Sarasota Arthritis Res Ctr

Recruiting

Sarasota,Florida,34239,United States

Jesse Boodoo

Advanced Rheumatology of Houston

Recruiting

Spring,Texas,77382,United States

David Derkacs
Tamar Brionez

Accurate Clinical Research Inc

Recruiting

San Antonio,Texas,78229,United States

Philip Waller

Clinical Research Inst of MI

Recruiting

Saint Clair Shores,Michigan,48081,United States

Andrew Sulich
Latrece Keaton

Center for Rheumatology Research

Recruiting

West Hills,California,91307,United States

Lauren Jackson
Nazanin Firooz

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals